Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective study of Goreisan and Saireito to prevent postoperative recurrence of chronic subdural hematoma
jRCTs051180131Completed
- Sponsor
- Kracie
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of oreongsan and saireito in Chronic subdural haematoma (CSDH) (2 arms), sponsored by Kracie. Primary endpoint: Symptomatic recurrence within 3 months. Started Apr 2017; status: completed.
02
Drugs
oreongsansaireito
03
Conditions
Chronic subdural haematoma (CSDH)
Beyond the preview
Go deeper on jRCTs051180131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180131.